Test Code ALWB Aluminum, Blood
Specimen Required
***This specimen container cannot be opened or used for any other testing before shipping.***
Patient Preparation: High concentrations of gadolinium and iodine are known to potentially interfere with most inductively coupled plasma mass spectrometry-based metal tests. If either gadolinium- or iodine-containing contrast media has been administered, a specimen should not be collected for 96 hours.
Supplies:
-Greiner Bio-One VACUETTE TUBE 6 mL NH Trace Elements Sodium Heparin tube (T819)
-Metal Free Specimen Vial (T173)
Container/Tube: Greiner Bio-One VACUETTE TUBE 6 mL NH Trace Elements Sodium Heparin tube
Specimen Volume: 1 mL
Collection Instructions: See Metals Analysis Specimen Collection and Transport for complete instructions.
Secondary ID
622056Useful For
Preferred test for routine aluminum screening
Monitoring metallic prosthetic implant wear
Special Instructions
Method Name
Triple-Quadrupole Inductively Coupled Plasma Mass Spectrometry (ICP-MS/MS)
Specimen Type
Whole bloodSpecimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Whole blood | Refrigerated | 14 days |
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Reference Values
0-17 years: Not established
≥18 years: <5 ng/mL
Interpretation
Internal exposure, which can be determined from aluminum levels in blood, is a significantly better measure for assessing aluminum-related neurotoxicity. Early signs of neurotoxicity have been reported in plasma concentrations starting at 13 ng/mL, but any elevation must take into account the full clinical history and other clinical signs and symptoms and test results. Previous studies have reported a whole blood to serum ratio for aluminum of approximately 1.7.(1)
The McCarthy(2) and Hernandez(3) describe a biochemical profile that is characteristic of aluminum overload disease in dialysis patients:
-Patients in kidney failure with no signs or symptoms of osteomalacia or encephalopathy usually had serum aluminum below 20 ng/mL and parathyroid hormone (PTH) concentrations above 150 pg/mL, which is typical of secondary hyperparathyroidism.
-Patients with signs and symptoms of osteomalacia or encephalopathy had serum aluminum above 60 ng/mL and PTH concentrations below 50 pg/mL (PTH above the reference range, but low for secondary hyperparathyroidism).
-Patients who had serum aluminum above 60 ng/mL but below 100 ng/mL were identified as candidates for later onset of aluminum-overload disease and required aggressive efforts to reduce their daily aluminum exposure. This was done by switching them from aluminum-containing phosphate binders to calcium-containing phosphate binders, by ensuring that their dialysis water had less than 10 ng/mL of aluminum, and ensuring the albumin used during postdialysis therapy was aluminum free.
Prosthesis wear is known to result in increased circulating concentration of metal ions.(4) A modest increase (6-10 ng/mL) in serum aluminum concentration is likely to be associated with a prosthetic device in good condition. Serum concentrations above 10 ng/mL in a patient with an aluminum-based implant not undergoing dialysis suggest significant prosthesis wear. Increased serum trace element concentrations in the absence of corroborating clinical information do not independently predict prosthesis wear or failure.
Method Description
The metal of interest is analyzed by triple-quadrupole inductively coupled plasma mass spectrometry.(Unpublished Mayo method)
Day(s) Performed
Tuesday through Friday
Report Available
1 to 5 daysSpecimen Retention Time
14 daysPerforming Laboratory

CPT Code Information
82108
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ALWB | Aluminum, B | 5575-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
622056 | Aluminum, B | 5575-6 |